Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Tc Biopharm [Holdings] Plc ADR (TCBP)

Tc Biopharm [Holdings] Plc ADR (TCBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,035
  • Shares Outstanding, K 677
  • Annual Sales, $ 0 K
  • Annual Income, $ -7,350 K
  • 60-Month Beta 0.32
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.32
Trade TCBP with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1800 +26.27%
on 04/01/24
3.2700 -54.43%
on 04/04/24
+0.1800 (+13.74%)
since 03/28/24
3-Month
0.8501 +75.27%
on 02/05/24
3.2700 -54.43%
on 04/04/24
+0.2600 (+21.14%)
since 01/29/24
52-Week
0.8501 +75.27%
on 02/05/24
26.6000 -94.40%
on 05/03/23
-20.7100 (-93.29%)
since 04/28/23

Most Recent Stories

More News
Why the Relapsed/Refractory Acute Myeloid Leukemia Market is Expected to Witness Revolutionary Developments

EQNX::TICKER_START (NASDAQ:TCBP),(NYSE:CVM),(NASDAQ:INVO),(NASDAQ:SNY),(NYSE:PFE) EQNX::TICKER_END

TCBP : 1.4900 (-2.61%)
CVM : 1.4100 (-2.08%)
INVO : 1.0600 (+8.16%)
SNY : 49.09 (-0.08%)
PFE : 25.64 (+0.94%)
TC BioPharm Announces Grant Funding in Collaboration with Queen Mary University of London (QMUL)

/PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical stage biotechnology company developing platform...

TCBP : 1.4900 (-2.61%)
TC BioPharm to Present at H.C. Wainwright 25th Annual Global Investment Conference

/PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform...

TCBP : 1.4900 (-2.61%)
TC BioPharm Maintains Nasdaq Listing

/PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform...

TCBP : 1.4900 (-2.61%)
TC BioPharm CEO, Bryan Kobel, is Featured on The Stock Day Podcast

Phoenix, Arizona--(Newsfile Corp. - July 6, 2023) - The Stock Day Podcast welcomed TC BioPharm Holdings, PLC. (NASDAQ: TCBP) ("the Company"), a clinical-stage biopharmaceutical company focused on the discovery,...

TCBP : 1.4900 (-2.61%)
TC BioPharm Increases Allogeneic Car and Partnering Focus for Advancement of TCB-008

/PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company today laid out a fundamental...

TCBP : 1.4900 (-2.61%)
TC BioPharm Announces Closing of $5.5 Million Public Offering

/PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform...

TCBP : 1.4900 (-2.61%)
TC BioPharm Announces Pricing of $5.5 Million Public Offering

/PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform...

TCBP : 1.4900 (-2.61%)
TC Biopharm Announces Corporate Restructuring, Reduction in Overhead

/PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform...

TCBP : 1.4900 (-2.61%)
TC BioPharm Receives Extension from Nasdaq Hearings Panel to Regain Compliance With Listing Rule 5550(b)(2)

/PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform...

TCBP : 1.4900 (-2.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

TC BioPharm plc is a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and viral indications. TC BioPharm plc is based in EDINBURGH, Scotland.

See More

Key Turning Points

3rd Resistance Point 1.7233
2nd Resistance Point 1.6767
1st Resistance Point 1.6033
Last Price 1.4900
1st Support Level 1.4833
2nd Support Level 1.4367
3rd Support Level 1.3633

See More

52-Week High 26.6000
Fibonacci 61.8% 16.7635
Fibonacci 50% 13.7250
Fibonacci 38.2% 10.6866
Last Price 1.4900
52-Week Low 0.8501

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar